Note 13 - Discontinued Operations	3 Months Ended
Mar. 31, 2020
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	13. Discontinued operations In September 2018, the Company and certain of its subsidiaries entered into a Limited Liability Company Interest Purchase Agreement, or the Purchase Agreement, with Quest, pursuant to which the Company sold its U.S. Laboratory Services Business to Quest, or the Transaction, for gross proceeds of $170 million in cash. Of this amount, approximately $32.3 million was paid directly to MidCap Financial Trust in settlement of all amounts due under the Company’s debt financing agreement, which included prepayment and exit fees of approximately $2.3 million. At the time of sale, the U.S. Laboratory Services Business had a carrying value of $27.9 million. The Company recorded a gain of $146.0 million in connection with the Transaction, which amount was included in income from discontinued operations before income taxes in the Company’s consolidated statement of operations during the three months ended December 31, 2018. Additionally, pursuant to the terms of the Purchase Agreement, the parties entered into certain ancillary agreements as of the Closing Date, including: (i) a transitional services agreement, or TSA, that was concluded in 2019, (ii) a technology license agreement that will remain in effect until the date of expiration or lapse of the last “Blood Stability Patent” to expire or lapse, and (iii) a long-term supply agreement, or the Supply Agreement, pursuant to which Quest agreed to purchase T-SPOT. TB test kits and related accessories. The Supply Agreement will last for a period of seven years after the effective date unless terminated earlier by a party to the Supply Agreement. In addition, the parties entered into a strategic collaboration agreement to drive continued growth of T-SPOT. TB testing in the U.S. that will remain in effect until the expiration or termination of the Supply Agreement. During the first quarter of 2020, the Company recorded a net charge from discontinued operations of $817,000 that included a correction of an immaterial prior period error of $925,000 related to a state tax assessment along with current taxes of $39,000, partially offset by a $147,000 adjustment on the remaining proceeds due from the Transaction.

13.

Discontinued operations

September 2018,

the Company and certain of its subsidiaries entered into a Limited Liability Company Interest Purchase Agreement, or the Purchase Agreement, with Quest, pursuant to which the Company sold its U.S. Laboratory Services Business to Quest, or the Transaction, for gross proceeds of

$170

million in cash. Of this amount, approximately

$32.3

million was paid directly to MidCap Financial Trust in settlement of all amounts due under the Company’s debt financing agreement, which included prepayment and exit fees of approximately

$2.3

million.

At the time of sale, the U.S. Laboratory Services Business had a carrying value of

$27.9

million. The Company recorded a gain of

$146.0

million in connection with the Transaction, which amount was included in income from discontinued operations before income taxes in the Company’s consolidated statement of operations during the

three

months ended

December 31, 2018.

Additionally, pursuant to the terms of the Purchase Agreement, the parties entered into certain ancillary agreements as of the Closing Date, including: (i) a transitional services agreement, or TSA, that was concluded in

2019,

(ii) a technology license agreement that will remain in effect until the date of expiration or lapse of the last “Blood Stability Patent” to expire or lapse, and (iii) a long-term supply agreement, or the Supply Agreement, pursuant to which Quest agreed to purchase T-SPOT.

test kits and related accessories. The Supply Agreement will last for a period of

seven

years after the effective date unless terminated earlier by a party to the Supply Agreement. In addition, the parties entered into a strategic collaboration agreement to drive continued growth of T-SPOT.

testing in the U.S. that will remain in effect until the expiration or termination of the Supply Agreement.

During the

first

quarter of

2020,

the Company recorded a net charge from discontinued operations of

$817,000

that included a correction of an immaterial prior period error of

$925,000

related to a state tax assessment along with current taxes of

$39,000,

partially offset by a

$147,000

adjustment on the remaining proceeds due from the Transaction.